Find disease awareness content and relevant supporting materials

The clinical course of heart failure is characterised by progressive worsening of cardiac function and symptoms. Patients progress to a condition where traditional treatment is no longer effective and advanced therapies...

Acute heart failure (AHF) is a leading cause of admission in emergency departments (ED).

The longer survival of patients with Duchenne muscular dystrophy due to advances in clinical care has increased the incidence of Duchenne muscular dystrophy-associated cardiomyopathy, a nearly consistent feature in the third decade...

Acute decompensated heart failure (ADHF) is associated with high morbidity and mortality.

This EFIM guideline critically appraises and adapts existing recommendations for managing acute heart failure (AHF) in internal medicine. It addresses diagnostic challenges, treatment strategies for hypotension and low cardiac output, and approaches to reduce rehospitalization and mortality in complex patient scenarios.

Aims: Levosimendan improves haemodynamics in acute decompensated heart failure (HF). However, it is increasingly used for repetitive or intermittent infusions in advanced but stable chronic HF, without clear indication...

Aims: The LION-HEART study was a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial evaluating the efficacy and safety of intravenous administration of intermittent doses of levosimendan in outpatients with advanced chronic heart failure.

Background: Acute heart failure (AHF) after ST-segment elevation myocardial infarction (STEMI) is usually treated with inotropic support or vasoactive medications.

Discover the latest advancements in heart failure management with the 2023 ESC Focused Update. This update incorporates groundbreaking evidence from recent trials, leading to new recommendations for treating HFmrEF, HFpEF, comorbidities, and Acute HF.

The 2023 HRS/APHRS/LAHRS guideline outlines best practices for cardiac physiologic pacing (CPP) to prevent or mitigate heart failure. It covers indications for CRT and CSP, patient selection, procedural management, and pediatric considerations, while identifying gaps for future research.